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Background: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoim-
mune disease involving multiple organs. It is currently accepted that several genetic, 
environmental, and hormonal factors are contributing to its development. Innate immunity 
may have a great influence in autoimmunity through Toll-like receptors. TLR-7 recogniz-
ing single-strand RNA has been involved in SLE. Its activation induces intracellular signal 
with attraction of MyD88 and NF-kBp65, leading to IFN-α synthesis which correlate with 
disease activity.
Objective: To assess the expression of TLR-7, MyD88, and NF-kBp65 in B lymphocytes 
of Mayan women with SLE.
Methods: One hundred patients with SLE and 100 healthy controls, all of them Mayan 
women, were included. TLR-7 was analyzed on B and T lymphocytes, and MyD88 and 
NF-kB only in B lymphocytes. Serum INF-α level was evaluated by ELISA.
results: Significant expression (p <  0.0001) of TLR-7 in B and T lymphocytes and 
serum IFN-α increased (p = 0.034) was observed in patients. MyD88 and NF-kBp65 
were also increased in B lymphocytes of patients. TLR-7 and NF-kBp65 expression 
correlated, but no correlation with INF-α and disease activity was detected.
conclusion: Data support the role of TLR-7 and signal proteins in the pathogenesis of 
SLE in the Mayan population of Yucatán.
Keywords: innate immunity, Toll-like receptor 7, interferon-α, systemic lupus erythematosus, pathogenesis
inTrODUcTiOn
Systemic lupus erythematosus (SLE) is an autoimmune disease of connective tissue characterized 
by B lymphocytes hyperactivity and autoantibodies against nuclear self-antigens. The disease has a 
worldwide distribution and predominantly affects women. The SLE pathogenesis is yet unknown 
but several genetic, hormonal, and environmental factors are contributing to its development (1–4). 
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The incidence of SLE patients varies according to the population 
studied (5, 6). Several studies have been conducted in patients 
from different populations (Asian, European, and American), 
but few in Mexican population. Mexico has an admixed Mestizo 
population with a genetic pool from the Amerindian and the 
Spanish (7). Mexican individuals with SLE appear to have a more 
severe disease and a lower age of onset than European women 
and a higher frequency of disease activity flares. Moreover, it 
has been reported that the prevalence of SLE in Yucatán (0.7%) 
is slightly higher than the national prevalence (0.6%) (8, 9), 
but immune studies have not been conducted in the Mayan 
population.
Studies have shown that abnormal stimulation of innate 
immunity may have a great influence on immunopathogenesis 
of SLE through Toll-like receptors (TLRs) (10, 11). Those are 
pattern-recognition receptors (PRR) that identify a broad range 
of pathogen-associated molecular patterns (PAMPs) (12, 13). So 
far, 11 human TLRs have been identified, and TLR-7 has been 
associated with SLE in both human and mouse models (14–19). 
This receptor is found on endosomes of several immune cells, 
mainly antigen-presenting cells, such as dendritic and B cells (20). 
The recognition and internalization, through the B cell receptor, 
of nuclear self-antigens released as a consequence of apoptosis in 
SLE patients, can activate TLR-7 in endosomes of B lymphocytes 
supporting its role in the production of autoantibodies (21–24). 
RNA-containing complexes must access the interior of the 
plasmacytoid dendritic cells (pDCs), through the Fc receptors, 
thus providing a route of entry for RNA to reach TLR-7, with 
the resulting INF-α production (25, 26). INF-α influences the 
development, progression, and pathogenesis of SLE (27–30). As 
a result of TLR-7 ligation, INF-α enhances TLR-7 signaling in 
pDCs forming a positive feedback loop (31, 32).
The TLR-7 ligation induce signal transduction via the myeloid 
differentiation primary-response protein 88 (MyD88), a common 
adaptor protein, which interacts with IRAK1/4 (Interleukin-1 
receptor-associated kinase 1/4) and TRAF6 (TNF receptor-
associated factor 6) to form the MyD88/IRAK1/IRAK4/TRAF6 
complex. Subsequently, IRAK1 and TRAF6 dissociate from the 
receptor complex and interact with kinases IKKB (IκB kinases) 
resulting in the activation of NF-kB (nuclear factor kappa-light-
chain-enhancer of activated B cells), permitting the expression of 
genes of proinflammatory cytokine and chemokines (33, 34). On 
the other hand, the transcription factor IRF-7 (Interferon regula-
tory factor 7) can bind to the MyD88/IRAK1/IRAK4 complex, 
and its activation is dependent upon TLR-7 requiring the TRAF3 
(TNF receptor-associated factor 3) protein, which joins IRAK1 
and IKKα kinases to produce IFN-α (34).
Previously, the copy number variation (CNV) of TLR-7 gene 
in 80 Mayan women with SLE was analyzed in our laboratory. 
We found that 10% of patients had more than two copies of the 
TLR-7 gene. These data suggest that increased CNV of the TLR7 
gene may be a risk factor in this population (35). However, the 
expression of TLR-7 and signaling proteins has not been analyzed 
in B lymphocytes of our patients. Our aim was to assess the TLR-
7, MyD88, and NF-kBp65 expression in B cells of Mayan women 
with SLE and to compare them to healthy controls. Protein expres-
sions were correlated with serum INF-α and disease activity.
MaTerials anD MeThODs
sle Patients
One hundred SLE women of Mayan origin were recruited at the 
Rheumatology outpatient of the Agustin O’Horán and ISSSTE 
Regional Hospital, Yucatán. Diagnosis was established according 
to the American College of Rheumatology (ACR) criteria (36), 
and disease activity was evaluated by SLEDAI score (37). One 
hundred healthy women of the same origin were studied as 
controls. All selected subjects included in the study gave their 
informed consent, according to the Declaration of Helsinki. 
The study was approved by the Research Ethics Committee of 
the Agustin O’Horán Hospital of Yucatán (CIE-008-1-11). All 
women gave 15 ml of venous peripheral blood in one collection.
cell isolation
Ten milliliters of venous peripheral blood were collected in hep-
arinized tubes. Peripheral blood mononuclear cells (PBMC) were 
isolated from each subject, either patient and control, by gradient 
centrifugation on Ficoll-Hypaque (NycoPrep 1.077, Axis-Shield 
PoC AS, Oslo, Norway), and the cell viability and concentration 
was determined by staining with trypan blue and counted in a 
Neubauer chamber. Cells were adjusted to a concentration of 
1 × 106 cells/ml in complete medium [RPMI 1640 supplemented 
with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/
ml streptomycin, and 2.0 mM l-glutamine].
Tlr-7, MyD88, and nF-kBp65 expression
Isolated PBMC (1  ×  106  cells/tube) were first incubated with 
surface monoclonal antibodies against CD19 (Clone 1D3) and 
CD4 (Clone RPA-T4) conjugated with fluorescein isothiocyanate 
(FITC) and allophycocyanin (APC), respectively (IMGENEX, 
San Diego, CA, USA), in darkness at 4°C for 30  min. The 
cells were then fixed and permeabilized using the IC-Flow kit 
(IMGENEX, 10083K Cat, San Diego, CA, USA), and incubated 
with monoclonal antibodies against TLR-7 (Clone 4G6), MyD88 
(Clone 4D6), and NF-kBp65 (Clone 2J10D7) conjugated with 
phycoerythrin (PE), in darkness at 4°C for 30 min. Mouse IgG 
conjugated with FITC, PE, and APC were included as isotype 
controls (all from IMGENEX, San Diego, CA, USA). The cells 
were finally washed and assessed by flow cytometry. A total of 
10,000 cells were analyzed in the flow cytometer (FACScalibur, 
BD Biosciences Corp., San Jose, CA, USA) using the Cell Quest 
software. The lymphocytes population was identified using the 
forward scatter (FSC) versus side scatter (SSC) distribution. The 
percentages of CD19+ B and CD4+ cells expressing TLR-7 and 
CD19+ B cells expressing MyD88 and NF-kBp65 were assessed. 
The relative fluorescence intensity (rFI) of TLR-7, MyD88, and 
NF-kBp65 was calculated based on the mean fluorescence inten-
sity of the sample (MFIs) compared with isotype control (MFIc), 
using the formula: rFI = MFIs − MFIc/MFIc.
interferon-alpha
Five milliliters of venous peripheral blood (without antico-
agulant) were selected from each patient and control subject 
to obtain serum. Serum levels of IFNα in were determined by 
VeriKine Human IFN-alpha Serum Sample ELISA kit, following 
FigUre 1 | Tlr-7 expression in B (cD19+) and T (cD4+) lymphocytes 
of sle patients (n = 100) and control subjects (n = 100), analyzed by 
flow cytometry. Results expressed as the percentage (a) and relative 
fluorescence intensity (rFI) (B) of TLR-7 are presented in scatter plots and 
mean with SEM. Wilcoxon matched-pairs signed rank test was used to 
assess the difference of expression among SLE patients and control subject. 
**p = 0.0004, ***p < 0.0001.
TaBle 1 | characteristics of sle patients.
Features sle patients (%) or mean ± sD (range)
Number 100
Age (year) 39.73 ± 12.8973 (18–69)
Disease duration (year) 8.11 ± 6.9101 (0.01–29)
SLEDAI
Non-active (SLEDAI > 4) 46%
Active (SLEDAI < 4) 54%
Locality in the Yucatán state
Mérida 54%
Progreso 4%
Motul 4%
Izamal 2%
Dzidzantún 2%
Other in Yucatán state 34%
Treatment
Prednisone 49%a
Mycophenolic acid 10%a
Azathioprine 32%a
Hydroxychloroquine 13%a
Deflazacort 24%a
Methotrexate 14%a
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
aPercentage of patients receiving the drug in combination with other one.
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lymphocytes expressing TLR-7 were found in patients compared 
to controls (p < 0.0001) (Figure 1A). The rFI of TLR-7 was signifi-
cantly higher in B lymphocytes of patients, but no difference was 
found between patients and controls (p = 0.1882) (Figure 1B). 
Furthermore, significant expression of TLR-7 was found in CD4+ 
T lymphocytes of patients with respect to controls (p < 0.0001), 
and the rFI of TLR-7 was higher in patients. Additionally, no cor-
relation between TLR-7 expression in CD19+ B lymphocytes and 
active disease (SLEDAI > 4) was observed (Figure 2).
Regarding MyD88 and NF-kBp65, both were expressed more 
in CD19+ B lymphocytes of patients (n =  50) than of controls 
(n = 50) (p < 0.0001) (Figure 3A). Only NF-kBp65 correlated 
with TLR-7 expression in B lymphocytes of patients (Figure 4). 
The rFI of both proteins was significantly increased in CD19+ 
B lymphocytes from patients (p < 0.0001) (Figure 3B), but no 
correlation with TLR-7 expression was observed (Figure S2 in 
Supplementary Material). No correlation with active disease 
(SLEDAI > 4) was observed with both proteins.
the directions of the supplier (PBL Assay Science Piscataway, NJ, 
USA). The kit quantitates human IFNα using a sandwich immu-
noassay, with an anti-secondary antibody conjugated to horse-
radish peroxidase (HRP) and tetramethylbenzidine (TMB) as 
substrate. The detection range of 12.5–1000 pg/ml was calculated 
using a standard curve. Each standard, blank, and sample test 
was run in duplicate. The absorbance was determined at 450 nm, 
using a microplate reader (BIOTEK Instrument, Inc., VT, USA).
statistical analysis
Wilcoxon matched-pairs signed rank test was used to assess 
the significance of any difference in values of TLR-7, MyD88, 
NF-kBp65 expression and IFNα serum, among SLE patients 
and control subjects (p < 0.05). Correlation analysis was done 
using the Pearson correlation coefficient. In all comparisons, the 
level of significance was p < 0.05, using the Graph Pad Prism 5 
software.
resUlTs
characteristics of sle Patients
All patients were under treatment, 54% of them had active disease 
determined by SLEDAI (>4), and most residents of the Merida 
city (54%), the rest from the surrounding Yucatán state. The 
average age of patients was 39.73  years with different times of 
evolution (Table 1).
expression of Tlr-7, MyD88, and 
nF-kBp65
A representative figure of the analysis by flow cytometry, as 
described in Section “Materials and Methods,” is shown in Figure 
S1 in Supplementary Material. A higher percentage of CD19+ B 
FigUre 4 | correlation analysis of Tlr-7 with MyDss and nF-kBp65 
expression in sle patients. Results are presented in scatter plots. 
Pearson correlation test was used to assess correlation, r = Pearson 
correlation coefficient; p < 0.05.
FigUre 3 | MyD88 and nF-kBp65 expression in B lymphocytes of sle 
patients (n = 50) and control subjects (n = 50), analyzed by flow 
cytometry. Results expressed as the percentage (a) and relative 
fluorescence intensity (rFI) (B) of MyD88 and XF-kBp65 is presented in 
scatter plots and mean with SEM. Wilcoxon matched-pairs signed rank test 
was used to assess the difference of expression among SLE patients and 
control subject. ***p < 0.0001.
FigUre 2 | correlation analysis of Tlr-7 expression (%) with active 
disease (sleDai > 4) in sle patients. Results are presented in scatter 
plots. Pearson correlation test was used to assess correlation, r = Pearson 
correlation coefficient; p < 0.05.
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serum iFn-α
IFN-α was variable in patients (7.6 ± 3.54 ng/μl) but significantly 
higher (p = 0.0001) compared to undetectable levels in controls 
(Figure 5). However, no correlation with TLR-7 expression and 
disease activity (SLEDAI > 4) was observed (Figure 6).
DiscUssiOn
This research represented the first report on the expression of 
TLR-7 and signal proteins MyD88 and NF-kBp65 in B lympho-
cytes of Mayan women with SLE. We observed significant increase 
of TLR-7 expression in B lymphocytes of SLE patients compared 
to control subjects, which was consistent with previous studies, 
even with different analysis procedures (38–41). The rFI of TLR7 
also was increased in B cells from patients. This suggested that 
overexpression of TLR-7 in B lymphocytes may be a common 
characteristic of SLE patients since TLR-7 are the main source 
of pathological antibodies for the disease. Moreover, correlation 
between the TLR-7 expression and disease severity has been 
reported in SLE patients; however, we did not find correlation 
probably due to therapy they already received. Further study is 
needed to clarify this discrepancy.
FigUre 5 | serum iFn-α in sle patients (n = 100) and controls 
subjects (n = 100) were detected by human iFn-α elisa, as 
described in section “Materials and Methods.” Results expressed as 
nanograms per picoliter of IFN-α are presented in scatter plots and mean 
with SEM. Wilcoxon matched-pairs signed rank test was used to assess the 
difference among SLE patients and control subject. ***p = 0.0001.
FigUre 6 | correlation analysis of serum iFn-α with Tlr-7 expression 
(%) and active disease (sleDai > 4) in sle patients. Results are 
presented in scatter plots. Pearson correlation test was used to assess 
correlation, r = Pearson correlation coefficient; p < 0.05.
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Although a high percentage of B lymphocytes expressing 
TLR-7 were observed in patients, different subtypes of CD4+ T 
cells also express TLRs (42). The TLR-7 has been reported on 
CD4+CD25+ T regulatory (Treg) cells, and TLR-7 activation 
increase their suppressor function by suppressing autoreactive 
lymphocytes, but defects in their number and function may 
contribute to pathogenesis of SLE (43–45). It has been reported 
IL-17 secretion by human CD4 T cells stimulated with TLR-7 
agonist, suggesting that TLR-7 ligation generates proinflamma-
tory cytokines that induces Th17 differentiation and establishes 
a link between TLR-7 interaction and Th17 cell differentiation 
(46). An imbalanced Th17/Treg ratio favoring Th17 cells has been 
reported in SLE patients (47). We observed higher expression of 
TLR-7 in CD4+ T cells in SLE patients, but subtypes of Treg and 
Th17 cells were not identified. Further researches are needed to 
strengthen the role of TLR-7 on these cells as a mechanism of 
action in autoimmunity.
Few studies have evaluated the expression of MyD88 in cells 
of SLE patients. Nakano et al. assessed the mRNA of MyD88 in 
Chinese patients B lymphocytes, and found no significant differ-
ence with controls (48). Chen et al. studied the role of the TLR-7 
signaling pathway in the pathogenesis of adult-onset Still’s disease 
(AOSD) and SLE, finding increased levels of mRNA of MyD88, 
TRAF6, IRAK-4, and IFN-α in mononuclear cell of SLE patients, 
which correlated with disease activity (49). Data suggested that 
overexpression of MyD88-dependent signaling molecules may be 
a pathogenesis mechanism in SLE. We found significant expression 
levels of MyD88 in B lymphocytes of patients by flow cytometry, 
but no correlation with TLR-7 expression and disease activity was 
found, suggesting that activation of TLR-7 signaling pathway in 
our SLE patients appeared to be unaffected by the disease activity. 
Further studies are needed to establish whether MyD88 expression 
levels correlate with its mRNA or are influenced by the activation 
of other intracellular receptors that share the molecule, and if the 
treatment received by patients has any impact on MyD88.
The NF-kBp65 is an inducible transcription factor that controls 
genes involved in inflammatory responses and play an important 
role in B lymphocytes maintenance (50–52). Genetic associations 
have been found between genes involved in NF-kBp65 signal-
ing pathway in Chinese SLE patients, highlighting the role of 
NF-kBp65 in autoimmunity (53). We found significantly higher 
expression levels of NF-kBp65 in B lymphocytes from SLE 
patients consistent with those reported (53), suggesting its con-
stitutive activation in B cells of patients; however, no correlation 
with TLR-7 expression and disease activity was observed. Data 
support its role in the mechanisms of autoimmunity, but further 
studies are needed to identify which receptor induces NF-kBp65 
activation, promoting the survival of autoreactive B lymphocytes 
in SLE patients, despite treatment received.
A hallmark of SLE is the elevated levels of INF-α in serum. 
Approximately 50% of patients have been shown to have dys-
regulated expression of genes involved in the INF pathway, which 
correlates with disease activity (54, 55). High levels of INF-α 
were detected in our patients, but no correlation with disease 
activity was found. It is important to note that although 54% of 
patients had active disease, and all of them showed variable levels 
of serum INF-α, inactive patients showed low and undetectable 
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